|
Randomized controlled trials with N-acetylcysteine as a prophylactic measure to prevent contrast-induced nephouropathy |
|||||||
| Reference |
Year |
Number of patients |
Reason for contrast administration |
Study design |
Dose/timing/route of administration of NAC |
Hydration regimen |
Main outcomea |
|
|
|||||||
| [22] |
2000 |
83 |
CT |
NAC + hydration versus hydration |
600 mg po, twice daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
RR 0.11 (95% CI 0.02–0.86) |
| [23] |
2002 |
123 |
Various |
NAC + hydration versus hydration |
600 mg po, twice daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
RR 1.18 (95% CI 0.45–3.12) |
| [24] |
2002 |
183 |
Various |
NAC + hydration versus hydration |
600 mg po, twice daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
RR 0.59 (95% CI 0.22–1.57) |
| [25] |
2002 |
54 |
CAG |
NAC + hydration versus hydration |
600 mg po, twice daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
RR 0.18 (95% CI 0.04–0.72) |
| [26] |
2002 |
79 |
CAG |
NAC + hydration versus hydration |
1200 mg po, 1 hour before and3 hours after contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
RR 1.2 (95% CI 0.55–2.63) |
| [27] |
2002 |
121 |
CAG |
NAC + hydration versus hydration |
400 mg po, twice daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
RR 0.14 (95% CI 0.03–0.57) |
| [28] |
2003 |
80 |
CAG |
NAC + hydration versus hydration |
150 mg/kg iv, immediately before contrast |
NAC group: 500 ml 0.9% saline before and 500 ml 0.9% saline 4 hours after contrast |
RR 1.20 (95% CI 0.55–2.63) |
| Control group: 1 ml/kg per hour 0.9% saline 12 hours before – 12 hours after |
|||||||
| [29] |
2003 |
179 |
Elective CAG |
NAC + hydration versus hydration |
600 mg po, twice daily day before and on day of contrast |
75 ml/hour 0.45% saline 12 hours before – 12 hours after contrast |
13% versus 12%; NS |
| [30] |
2003 |
200 |
Elective CAG |
NAC + hydration versus hydration |
600 mg po, twice daily, day before and on day of contrast |
1 ml/kg per hour 0.9% saline 12 hours before – 6 hours after contrast |
RR 0.32 (95% CI 0.11–0.96) |
| [31] |
2003 |
108 |
CAG |
NAC + hydration versus hydration |
1200 mg iv, 12 hours before and immediately after contrast |
20 ml/hour 5% dextrose 12 hours before – 12 hours after contrast |
3.8% versus 5.9%; NS |
| [32] |
2003 |
43 |
Elective CAG |
NAC + hydration versus hydration |
600 mg po, twice daily, day before contrast; and 600 mg po three times daily, day of contrast |
1–2 ml/kg per hour 0.45% saline for 4–12 hours before – 75 ml/hour 0.45% saline for 12 hours after contrast |
4.8% versus 31.8%;P = 0.046 |
| [13] |
2003 |
96 |
Elective CAG |
NAC + hydration versus hydration |
375 mg po, twice daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
RR 1.28 (95% CI 0.30–5.41) |
| [33] |
2004 |
223 |
Various |
Low-dose versus high-dose NAC |
600 mg po twice daily versus 1200 mg po twice daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
11% versus 3.5%; P = 0.038 |
| [34] |
2004 |
91 |
Cardiovascular procedures |
NAC + hydration versus hydration |
400 mg po, three times daily, day before and on day of contrast |
100 ml/hour 0.9% saline 12 hours before – 12 hours after contrast |
17.4% versus 13.3%; NS |
| [35] |
2004 |
80 |
CAG |
NAC + hydration versus hydration |
600 mg po, three times daily, day before and on day of contrast |
1 ml/kg per hour 0.45% saline 12 hours before – 12 hours after contrast |
10% versus 8%; NS |
|
aIncidences of contrast-induced nephouropathy. CAG, coronary angiography; CI, confidence interval; CT, computed tomography, iv, intravenously; NAC, N-acetylcysteine; NS, not significant; po, by mouth; RR, relative risk. | |||||||
van den Berk et al. Critical Care 2005 9:361 doi:10.1186/cc3028 |
|||||||